Primary uveal melanoma specimens, fixed in formaldehyde and paraffin embedded, from 152 consecutive patients were available for this study. All patients had undergone enucleation at a date when this treatment was the sole therapeutic option available in Sweden. Twenty lesions were deemed extensively necrotic (defined as >50% of cells necrotic) and excluded from further evaluation, leaving 132 lesions to be immunostained as outlined herein. These lesions were from 55 female and 77 male patients (average age, 63 years; range, 25–85). Although 55 patients succumbed to metastatic uveal melanoma, 26 patients died of causes unrelated to uveal melanoma, and 51 patients were alive at the end of follow-up. The mean follow-up time was 4.8 years (range, 0.08–7.6) for patients who died of disseminated uveal melanoma, 8.2 years (range, 0.4–21.7) for patients who died of other causes, and 12.3 years (range, 1.1–21) for the survivors. All specimens had been independently examined by an experienced ophthalmic pathologist and assessed for tumor location within the uvea, tumor cell type, and largest tumor diameter and tumor height. Briefly, specimens included 11 ciliary body tumors, 53 anterior choroidal tumors, and 65 tumors confined to the posterior choroid. Fifty-five tumors were spindle cell melanoma, 23 tumors were of a mixed cell type, 9 were epithelioid melanoma, and 45 were partially necrotic. The median largest tumor diameter was 12.5 mm (range, 6–22 mm), and the median tumor height was 7.3 mm (range, 2–17 mm). The study conformed to the tenets of the Declaration of Helsinki and was approved by the ethics committee of the Karolinska Institutet.